Inspire Pharmaceuticals Inc

Inspire Pharmaceuticals — Corporate Update (January 2009)

11 slides from Inspire Pharmaceuticals's corporate update, Jan 27, 2009

  1. Slide 1: Prolacria Program Background Information

    Inspire Pharmaceuticals Prolacria™ Program Background Information January 27, 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which convey management's expectations, beliefs, plans and objectives regarding future performance. These statements discuss matters that are not facts

  3. Slide 3: Dry Eye Disease

    Dry Eye Disease Disorder of the tear film that causes damage to the ocular surface and symptoms of ocular discomfort and fluctuating vision Heterogeneous disease characterized by reduced tear production, defective tear film composition and/or evaporative loss of fluid Causes damage to the ocular sur

  4. Slide 4: Diquafosol Tetrasodium: Novel Molecule

    Diquafosol Tetrasodium: NovelMolecule Discovered byInspireforDryEye O O HN HN O N O N O O O O O P O P O P O P O O - - - - O O O O O OH OH 4 Na + OH OH P1,P4-di (uridine 5’-) tetraphosphate, tetrasodium salt Potent and selective agonist 2atreceptor P2Y on corneal and conjunctival epithelial surfaces

  5. Slide 5: Prolacria Phase 3 Environmental Clinical Testing

    TM Prolacria Phase3 Environmental ClinicalTesting Study Clinical Size Duration Primary Efficacy Endpoint Phase (ITT) 03-104 3 544 12 weeks + 40 Reduction in mean corneal staining & weeks for safety worst symptom score Environmental 03-105 3 519 24 weeks Reduction in mean corneal staining & Environme

  6. Slide 6: Improvements in Mean Central Corneal Staining

    Improvements In Mean Central Corneal Staining Reduction of mean central corneal staining scores in Phase 3 environmental trials for all patients, regardless of baseline staining (Intent-to-Treat Population) 03-104 03-105 03-109 Placebo Prolacria Placebo Prolacria Placebo Prolacria p-value p-value p-

  7. Slide 7: Clearing of Central Corneal Staining

    Clearing of Central Corneal Staining Proportion of all patients, regardless of baseline staining, that achieved clearing of central corneal staining (NEI score of 0) at Week 6 Endpoint in the Phase 3 environmental trials (Intent-to-Treat Population) 03-104 03-105 03-109 Placebo Prolacria Placebo Pro

  8. Slide 8: Clearing of Central Corneal Staining in Patients With Baseline Scores of 2 or 3

    Clearing of Central Corneal Staining in Patients With Baseline Central Corneal Staining Scores of 2 or 3 Proportion of patients with a baseline NEI staining score of 2 or 3 in the central cornea thatachievedclearingofcentralcornealstaining(NEIscoreof0)atWeek6 Endpoint in the Phase 3 environmental tr

  9. Slide 9: Clearing of Central Corneal Staining in Patients With Baseline Score of 3

    Clearing of Central Corneal Staining in Patients With Baseline Central Corneal Staining Score of 3 Proportion of patients with a baseline NEI staining score of 3 in the central cornea that achieved clearing of central corneal staining (NEI staining score of 0) at Week 6 Endpoint in the Phase 3 envir

  10. Slide 10: Recent Regulatory History

    Recent Regulatory History TM OriginalNDAforProlacria submitted June2003aftertwoPhase3 clinical trials (03-104 and 03-105) Approvable Letter received from FDA in Dec 2003 NDA amendment filed June 2005 (with results from two additional clinical trials03-108 – and 03-109) Second Approvable Letter recei

  11. Slide 11: Prolacria Phase 3 Environmental Clinical Trial (03-113)

    TM Prolacria Phase 3 Environmental Clinical Trial (03-113) R Primary Endpoint: A Prolacria • Proportion of subjects N = 450 N (diquafosol tetrasodium receiving Prolacria that Inclusion Criteria: ophthalmic solution 2%) achieve clearing of • Corneal fluorescein staining D QID fluorescein staining of

Inspire Pharmaceuticals — Corporate Update (January 2009) on 6ix